How big is the carcinoid tumor market today, and what are its future growth expectations?
The carcinoid tumor market size has grown rapidly in recent years. It will grow from $1.61 billion in 2024 to $1.78 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to increasing incidence of neuroendocrine tumors, rising awareness about rare cancers, improving healthcare infrastructure, availability of targeted therapies, and expansion of clinical trials for new treatment options.
The carcinoid tumor market size is expected to see rapid growth in the next few years. It will grow to $2.65 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to growing demand for personalized medicine, increasing focus on early detection and diagnosis, rising adoption of minimally invasive surgeries, expanding research on novel therapies, and increasing use of molecular targeted therapies. Major trends in the forecast period include integration of AI and machine learning in diagnostics, shift toward combination therapies, telemedicine and remote monitoring, patient-centric care, collaborative research.
Get Your Free Sample of The Global Carcinoid Tumor Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21127&type=smp
What have been the primary factors driving the carcinoid tumor market’s growth?
The growing obese population is expected to propel the growth of the carcinoid tumor market going forward. The obese population refers to individuals whose body mass index (BMI) is 30 or higher, indicating excessive body fat. The growing obese population is attributed to factors such as poor dietary habits, lack of physical activity, sedentary lifestyles, and increased consumption of processed and high-calorie foods. Obesity contributes to carcinoid tumor development by promoting chronic inflammation, insulin resistance, and increased secretion of growth factors that support tumor growth. For instance, in September 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2022, 22 states reported an adult obesity rate of 35% or higher, up from 19 states in 2021. Therefore, the growing obese population is driving the growth of the carcinoid tumor market.
What are the key segments within the carcinoid tumor market?
The carcinoid tumor market covered in this report is segmented –
1) By Disease Type: Gastrointestinal Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor, Lung Neuroendocrine Tumor, Other Disease Types
2) By Treatment: Octreotide, Lanreotide, Telotristat ethyl, Capecitabine (Xeloda), 5-Fluorouracil (5-FU), Doxorubicin (Adriamycin), Etoposide (VP-16), Dacarbazine (DTIC), Streptozocin, Other Treatments
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Online Channel, Offline Channel
5) By End User: Hospital And Clinics, Academic Institutions, Research Organizations
Subsegments:
1) By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors, Appendiceal Neuroendocrine Tumors
2) By Pancreatic Neuroendocrine Tumor: Insulinoma, Non-insulinoma, Glucagonoma
3) By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors, Atypical Carcinoid Tumors
4) By Other Disease Types: Thymic Neuroendocrine Tumors, Ovarian Neuroendocrine Tumors
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/carcinoid-tumor-global-market-report
Which key players are shaping the carcinoid tumor market?
Major companies operating in the carcinoid tumor market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Siemens Healthineers AG, Boston Scientific Corporation, Boehringer Ingelheim International GmbH, Catalent Inc, Ipsen S.A., Exelixis Inc, Novocure Limited, Hutchison MediPharma Limited (A subsidiary of HUTCHMED), Tarveda Therapeutics Inc., Lexicon Pharmaceuticals Inc., Dauntless Pharmaceuticals Inc.
How will emerging trends drive the carcinoid tumor market throughout the forecast period?
Major companies operating in the carcinoid tumor market are focusing on advancements in diagnostic technologies, such as the fully automated chromogranin A test, to enhance early detection and improve treatment outcomes. The automated chromogranin A (CgA) test refers to a fully automated diagnostic tool used to measure levels of chromogranin A, a biomarker commonly associated with neuroendocrine tumors, including carcinoid tumors. For instance, in October 2023, Thermo Fisher Scientific Inc., a US-based biotechnology research company, received FDA clearance for its Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR immunoassay. This marks the first FDA-approved Chromogranin A (CgA) test and the only automated immunoassay globally for monitoring tumor progression in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients. Designed to measure CgA concentration in human serum, the assay enables laboratories and cancer centers to track tumor growth and assess treatment efficacy. By replacing manual laboratory-developed tests, it enhances lab efficiency and ensures clearer result interpretation. The test operates on the Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS random-access immunoassay analyzer, utilizing TRACE technology to deliver precise results in under 30 minutes.
How do regional factors impact the carcinoid tumor market, and which region is the largest contributor?
North America was the largest region in the carcinoid tumor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoid tumor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Carcinoid Tumor Market Report 2025 Offer?
The carcinoid tumor market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
A carcinoid tumor is a rare, slow-growing type of neuroendocrine tumor that typically arises in the gastrointestinal tract or lungs. It originates from enterochromaffin cells, which produce and release hormones such as serotonin. Symptoms may vary depending on the tumor’s location and whether it secretes hormones, potentially causing carcinoid syndrome.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21127
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
